TY - JOUR
T1 - Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro
AU - Han, Seong Su
AU - Son, Dong Ju
AU - Yun, Hwakyung
AU - Kamberos, Natalie L.
AU - Janz, Siegfried
N1 - Funding Information:
This work was supported in part by Korea Research Foundation Grant KRF-2007-357-E00032 provided to D.J.S. by the Korean Government (MOEHRD). This work was also supported, in part, by research awards from the International Waldenström's Macroglobulinemia Foundation and R01CA151354 from the NCI. The authors would like to thank Dr. Van S. Tompkins for his careful reading of the paper.
PY - 2013/2
Y1 - 2013/2
N2 - Piperlongumine (PL), a pepper plant alkaloid from Piper longum, kills solid tumor cells in a highly selective, potent fashion. To evaluate whether PL may have similar effects on malignant blood cells, we determined the efficacy with which PL inhibits the B-lymphocyte derived neoplasm, Burkitt lymphoma (BL). Low micromolar concentrations of PL (IC50=2.8μM×8.5μM) curbed growth and survival of two EBV+ BL cell lines (Daudi, Raji) and two EBV BL cell lines (Ramos, DG-75), but left normal peripheral blood B-lymphocytes unharmed. PL-dependent cytotoxicity was effected in part by reduced NF-κB and MYC activity, with the former being caused by inhibition of IκBα degradation, nuclear translocation of p65, and binding of NF-κB dimers to cognate DNA sequences in gene promoters. In 4 of 4 BL cell lines, the NF-κB/MYC-regulated cellular target genes, E2F1 and MYB, were down regulated, while the stress sensor gene, GADD45B, was up regulated. The EBV-encoded oncogene, LMP-1, was suppressed in Daudi and Raji cells. Considering that NF-κB, MYC and LMP-1 play a crucial role in the biology of many blood cancers including BL, our results provide a strong preclinical rationale for considering PL in new intervention approaches for patients with hematologic malignancies.
AB - Piperlongumine (PL), a pepper plant alkaloid from Piper longum, kills solid tumor cells in a highly selective, potent fashion. To evaluate whether PL may have similar effects on malignant blood cells, we determined the efficacy with which PL inhibits the B-lymphocyte derived neoplasm, Burkitt lymphoma (BL). Low micromolar concentrations of PL (IC50=2.8μM×8.5μM) curbed growth and survival of two EBV+ BL cell lines (Daudi, Raji) and two EBV BL cell lines (Ramos, DG-75), but left normal peripheral blood B-lymphocytes unharmed. PL-dependent cytotoxicity was effected in part by reduced NF-κB and MYC activity, with the former being caused by inhibition of IκBα degradation, nuclear translocation of p65, and binding of NF-κB dimers to cognate DNA sequences in gene promoters. In 4 of 4 BL cell lines, the NF-κB/MYC-regulated cellular target genes, E2F1 and MYB, were down regulated, while the stress sensor gene, GADD45B, was up regulated. The EBV-encoded oncogene, LMP-1, was suppressed in Daudi and Raji cells. Considering that NF-κB, MYC and LMP-1 play a crucial role in the biology of many blood cancers including BL, our results provide a strong preclinical rationale for considering PL in new intervention approaches for patients with hematologic malignancies.
UR - http://www.scopus.com/inward/record.url?scp=84872374148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872374148&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2012.11.009
DO - 10.1016/j.leukres.2012.11.009
M3 - Article
C2 - 23237561
AN - SCOPUS:84872374148
SN - 0145-2126
VL - 37
SP - 146
EP - 154
JO - Leukemia Research
JF - Leukemia Research
IS - 2
ER -